Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2006-09-05
2006-09-05
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C530S387100, C530S388240, C530S389200
Reexamination Certificate
active
07101547
ABSTRACT:
The present invention provides methods for preventing or treating a disease in a subject which is caused by an inflammatory response to a disease or syndrome which is mediated by endogenous substance P. These methods comprise the administration to the subject of a pharmaceutically-effective amount of anti-substance P antibodies, or anti-substance P antibody fragments, such as F(ab)2fragments, thereby inhibiting the activity of endogenous substance P in the subject. By inhibiting the activity of endogenous substance P in the subject, the levels of cytokines produced by T lymphocytes present in the subject are reduced, the signals which direct the inflammatory response to the infection become altered, and the amount of cytokine-induced inflammation becomes reduced. Respiratory syncytial virus is one example of an agent which causes an infection which often results in a disease caused by an inflammatory response to the infection mediated by endogenous substance P. Generally, from about 0.001 mg to about 10 g of anti-substance P antibodies, or anti-substance P antibody fragments, per kilogram of body weight per day are administered to a mammalian subject, with from about 1 mg to about 1000 mg of anti-substance P antibodies, or anti-substance P antibody fragments, per kilogram of body weight per day being preferred.
REFERENCES:
patent: 4419352 (1983-12-01), Cox et al.
patent: 5256766 (1993-10-01), Coughlin
patent: 5332817 (1994-07-01), Desai et al.
patent: 5340822 (1994-08-01), Emonds-Alt et al.
patent: 5373003 (1994-12-01), Lowe, III
patent: 5410019 (1995-04-01), Coy et al.
patent: 5451586 (1995-09-01), Lowe, III
patent: 5464820 (1995-11-01), Burton et al.
patent: 5484804 (1996-01-01), Achard et al.
patent: 5498614 (1996-03-01), Desai et al.
patent: 5604241 (1997-02-01), Ito et al.
patent: 5620989 (1997-04-01), Harrison et al.
patent: 5688806 (1997-11-01), Desai et al.
patent: 6034105 (2000-03-01), Mendel
patent: WO 92/16547 (1992-10-01), None
patent: WO 96/29326 (1996-09-01), None
Kudlacz, EM et al. Eur. J. Pharmacol. [1994] 270:291-300.
Jafarian, A et al. Life Sciences [1995] 57(2):143-153.
Larsen, GL. Clin. Resp. Physiol. [1986] 22(suppl. 7):35-37.
Hemmingsson, P et al. Scand. J. Infect. Dis. [1993] 25(6):783-785.
Moneret-Vautrin, DA et al. Rhinology [1992] 30(3):161-168.
Agro et al., “Inhibition of Murine Intestinal Inflammation by Anti-Substance P Antibody,”Regional Immunology, 5:120-126, 1993.
Couraud et al., “Anti-substance P Anti-idiotypic Antibodies,”Journal of Biological Chemistry, 260(16):9461-9469, 1985.
Jafarian et al., “Passive Immunization with an Anti-Substance P Antibody Prevents Substance P-and Neurokin A-Induced Bronchospasm in Anesthetized Guinea-Pigs,”Life Sciences, 57(2):143-153, 1995.
Maillet et al., “Anti-substance P anti-idiotypic antibodies modulate the secretory process in the rat parotid gland in vitro,”European Journal of Pharmacology, 187:357-367, 1990.
Piccioli et al., Neuroantibodies: Ectopic Expression of a Recombinant Anti-Substance P Antibody in the Central Nervous System of Transgenic Mice,Neuron, 15:373-384, 1995.
Swenberg et al., “Development of an anti-idiotypic that blocks substance P primary antibodies and substance P membrane binding,”Brain Research, 417:131-138, 1987.
Tripp et al., “Respiratory Syncytial Virus Infection and G and/or SH Protein Expression Contribute to Substance P, Which Mediates Inflammation and Enhanced Pulmonary Disease in BALB/c Mice,”Journal of Virology, 74(4):1614-1622, 2000.
Anderson Larry J.
Moore Deborah D.
Tripp Ralph A.
Chan Christina
Klarquist & Sparkman, LLP
The United States of America as represented by the Secretary of
VanderVegt F. Pierre
LandOfFree
Method for the prevention and treatment of diseases caused... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the prevention and treatment of diseases caused..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the prevention and treatment of diseases caused... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3618243